Compare Nutanix Inc (NTNX) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nutanix Inc vs Repligen Corporation Common Stock — how do they compare? Nutanix Inc trades at $69.68 (market cap $19.72B), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B). The key difference: Nutanix Inc is the larger of the two by market cap, and Nutanix Inc is more actively traded (2,236,075 versus 1,259,263). Which is the better fit depends on your goals — on Pluang, investors hold Nutanix Inc for 17 Days and Repligen Corporation Common Stock for 0 Days on average.
| NTNX | RGEN | |
|---|---|---|
Market Cap | $19.72B | $11.14B |
Volume | 2,236,075 | 1,259,263 |
Sector | Technology | Health |
52-Week High | $74.63 | $194.57 |
52-Week Low | $34.41 | $102.87 |
Typical Hold Time | 17 Days | 0 Days |
Enterprise Value | $18.88B | $11.02B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nutanix (NTNX) trades at $72.88, down 1.7% on the day but maintains strong technical momentum with bullish moving averages and positive analyst sentiment. The company demonstrates robust fundamentals with consistent earnings beats, including Q2 2026 EPS of $0.60 beating expectations of $0.49, and impressive 86.8% gross margins. Recent Gartner Magic Quadrant recognitions highlight competitive strength in virtualization and container management platforms.
Outlook remains positive with 62.5% analyst buy ratings and $76.11 consensus price target, though elevated P/E of 14.1 and negative ROE of -395.76% warrant caution. Key risks include supply chain pressures and competitive IT services market, while AI growth initiatives and external storage expansion present upside potential.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nutanix Inc
Nutanix, Inc. is a global leader in cloud software and hyperconverged infrastructure (HCI) solutions. The company's platform converges computing, virtualization, and storage into a single, seamless software-defined solution, enabling private, hybrid, and multi-cloud environments. Nutanix helps organizations simplify data center operations, manage their applications across various cloud platforms, and reduce IT complexity, positioning it as a key enabler of modern hybrid cloud strategies.
Read more on NTNX →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
